The viscosupplementation market was valued at USD 5.81 billion in 2024, the base year, and is projected to reach USD 6.39 billion in 2025 and USD 15.26 billion by 2034, growing at a CAGR of 10.1% during the forecast period 2025–2034, according to Polaris Market Research. Rising prevalence of osteoarthritis and joint disorders is increasing demand for minimally invasive treatments that reduce pain, enhance mobility, and lessen reliance on surgery. Key players include Sanofi, Fidia Farmaceutici S.p.A, Seikagaku Corp., Anika Therapeutics, Inc., DePuy Synthes, Zimmer Biomet, and Smith & Nephew PLC.

How Viscosupplementation Works

Viscosupplementation is a minimally invasive procedure involving the direct injection of a gel-like fluid, composed of exogenous hyaluronic acid (HA) derivatives, into the knee joint. The fluid acts as a lubricant that supports smooth bone movement, reduces inflammation, and serves as a shock absorber for joint loads.

By decreasing friction, enhancing synovial fluid cushioning, and improving range of motion, the therapy restores the rheological properties of synovial fluids and provides mechanical, analgesic, anti-inflammatory, and chondroprotective effects. This joint lubrication benefit underpins its use for osteoarthritis in the knee, hip, and hand, with formulations available in low, intermediate, and high molecular weights.

Demand Driver: Rising Prevalence of Knee Osteoarthritis

Knee osteoarthritis is one of the most common forms of arthritis, causing significant pain, reduced mobility, and decreased quality of life. According to WHO, in 2023 approximately 73% of osteoarthritis patients were aged 55 and above, with females making up 60% of the affected population, and the knee was the most affected joint, with 365 million cases. Prevalence is rising with lifestyle factors such as obesity, physical inactivity, and chronic diseases including hypertension and diabetes.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/viscosupplement-market  

Viscosupplementation has emerged as a popular non-surgical alternative for patients with mild to moderate knee osteoarthritis who seek pain relief and improved mobility. Growing awareness of its effectiveness, coupled with the rising number of patients seeking relief from knee osteoarthritis, positions the market for continued growth.

Aging Population and Formulation Advances

The growing aging population is a key factor in market expansion. Older adults are more susceptible to joint degeneration, and as they seek non-invasive solutions to manage symptoms, viscosupplementation has become a preferred option and an attractive alternative to surgery, especially for elderly patients. Alongside the aging population, factors such as smoking, a sedentary lifestyle, and other lifestyle changes are contributing to increased demand for osteoarthritis and osteoporosis treatments.

Advances in hyaluronic acid formulation, including cross-linked hyaluronic acid and combination therapies, are improving treatment durability and patient satisfaction, driving innovation within the market.

Regional Insights

Asia Pacific accounted for the largest share in 2024, supported by its aging population, rising prevalence of knee osteoarthritis, and increasing awareness of non-surgical treatment options. China, Japan, and India have seen significant demand because of large elderly populations and higher osteoarthritis incidence. Improved healthcare infrastructure, government support for affordable treatments, the availability of advanced hyaluronic acid-based products, and an expanding middle class have further contributed to growth.

Europe is expected to witness the fastest growth during the forecast period, driven by a rising geriatric population and increased investments from market players.

Competitive Landscape

The market is highly competitive, with global and regional players strengthening their positions through innovation, partnerships, and strategic expansions. Leading companies are developing advanced hyaluronic acid formulations, including single-injection and cross-linked variants, to enhance efficacy and patient compliance. Sanofi, Fidia Farmaceutici, Seikagaku Corporation, and Anika Therapeutics are leveraging research and development to maintain a competitive edge.

The full key player list also includes F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals B.V., LG Life Sciences Ltd., and Lifecore Biomedical. The report's Porter's Five Forces analysis rates rivalry among existing firms as high.

Conclusion

The viscosupplementation market is expected to grow steadily due to the rising prevalence of osteoarthritis, an aging population, and increasing demand for minimally invasive joint pain treatments. Advancements in hyaluronic acid therapies and growing healthcare awareness are expected to create new opportunities, despite challenges related to treatment costs and varying clinical outcomes.

More Trending Latest Reports By Polaris Market Research:

Ultraviolet Disinfection Equipment Market

Single-Use Bioreactors Market

Cold Plasma Market

Viscosupplementation Market

Restaurant Point-Of-Sale (POS) Terminals Market

Mobile Point-Of-Sale (MPOS) Terminals Market

EV Charging Station Market

Battery Management System Market

Stucco Market

Kitchen Appliances Market